Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Research & Development Cancer

Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?

Executive Summary

CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.

You may also be interested in...



Keeping Track: FDA's Review Actions Carry On During Shutdown

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review

The latest drug development news and highlights from our US FDA Performance Tracker. 

Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer

Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.

Table

View full table

Related Content

Pink Sheet
Scrip

Topics

Related Companies

Tags:
Clinical Trials Research & Development Cancer
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC100227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By